Lung Cancer

CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation.

Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low.

Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups.

Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations.

A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated.

Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer.

Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy.

Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans.

When clinicians and patients rely on different terminology for the term “cure” in cancer treatment, it can lead to patient dissatisfaction and confusion.

Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival.